NACDS Foundation, Wyeth join to launch pharmacy faculty award
ALEXANDRIA, Va. With a grant from pharmaceutical firm Wyeth, the National Association of Chain Drug Stores Foundation today unveiled a new addition to the NACDS Foundation Awards Program that honors community pharmacy faculty.
The $5,000 award will go each year to a pharmacy school faculty member who has made significant contributions to the practice of community pharmacy, according to the foundation. Among the contributions that will be considered: sustained exemplary service to help advance patient care capabilities in community pharmacy, a single outstanding achievement, or a combination of accomplishments that have advanced patient care in community pharmacy practice.
“We are pleased to partner with Wyeth in establishing this new award program which recognizes the important role pharmacy faculty play in preparing students to advance patient care in community pharmacy,” said NACDS Foundation president Phil Schneider.
The deadline for application materials will be March 1 annually. A $5,000 award will be bestowed upon the recipient’s academic institution, for a project in the recipient’s area of community pharmacy practice.
Amgen, Takeda cancer drug trials stopped after deaths
NEW YORK Several deaths have brought phase 3 clinical trials of a cancer drug by Amgen and Takeda Pharmaceutical to a halt.
The two companies are investigating the drug, motesanib, as an initial treatment for small-cell lung cancer, to be used in conjunction with chemotherapy.
A committee monitoring the 600-patient study found more had died early using the drug than those receiving placebo.
“While we are disappointed in the outcome, it is consistent with data seen with some other anti-VEGF therapies and appears to constitute a class effect of these types of agents,” Amgen executive vice president for research and development Roger Perlmutter said in a statement.
Elan appoints Paya as president
SOUTH SAN FRANCISCO, Calif. Elan Corp. has appointed Carlos Paya as president, the company announced Thursday.
Paya will work from Elan?s South San Francisco, Calif., campus, focusing on leading the company’s scientific, clinical and medical initiatives.
“As an immunologist, a former vice dean of clinical investigation at the Mayo Clinic and as a successful industry executive, Dr. Paya has a unique set of attributes and experiences that perfectly match the opportunities and challenges facing Elan,” said Elan chairman of the board Kyran McLaughlin in a statement.
Paya previously worked at Eli Lilly & Co. as vice president of Lilly Research Labs and global leader of the Diabetes and Endocrine Platform. He had served as an executive at Lilly since 2001. He also worked for six years at the Mayo Clinic as professor of medicine, immunology and pathology, in addition to his position as vice dean.